PNC Financial Services Group’s Monopar Therapeutics MNPR Stock Holding History

PNC Financial Services Group’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$556	Buy	+6	New	+$371	﹤0.01%	4961

Other funds holding MNPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Gerber LLC Columbus, Ohio $213M AUM 25.63% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

MIM

Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return

PNC Financial Services Group's MNPR Position: Q2 2026 in Review

PNC Financial Services Group opened a new position in Monopar Therapeutics (MNPR) in Q2 2026: 6 shares worth $556. The stake represents ﹤0.01% of the portfolio and ranks #4961 among its holdings.

19 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

PNC Financial Services Group held 6 shares of Monopar Therapeutics worth $556 as of Q2 2026.
Monopar Therapeutics was a new PNC Financial Services Group position in Q2 2026.
Monopar Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4961 holding.
19 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.